Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + Maviret retreatment for hepatitis C with NS5A resistance
ACTRN12620000794909Phase 4Not yet recruiting
- Sponsor
- Auckland District Health Board
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glecaprevir + pibrentasvir and sofosbuvir in hepatitis C virus infection, sponsored by Auckland District Health Board. Primary endpoint: Sustained virologic response. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
glecaprevir + pibrentasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ACTRN12620000794909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000794909.